Instant Dissolution, Rapid Absorption

Oral drug bioavailability faces challenges due to poor solubility and permeability in many pharmaceutical compounds.

Our HyDES formulation technology specifically targets and enhances solubility and bioavailability for APIs, particularly those with high melting points and a weakly basic nature, thereby advancing oral drug delivery and therapeutic effectiveness.


The HyDES platform creates a hydrophilic eutectic solvent capable of incorporating up to 30% drug load, easily encapsulated in standard gelatin capsules. In humans, this formulation induces a supersaturated state, enhancing drug absorption. Demonstrated in a case study with Atazanavir, a notoriously insoluble drug, HyDES significantly raised bioavailability — over 700% compared to crystalline API and by more than 75% against an amorphous solid dispersion.



The HyDES platform extends its applicability to formulate Proteolysis Targeting Chimeras (PROTACs). Learn more about PROTAC formulation development here.

Atazanavir in vivo Case Study

►Interested in how our eutectic technology compares to the traditional amorphous solid dispersion? Read our comprehensive comparison as we explore the differences between Amorphous Solid Dispersions (ASD) and SeraNovo's innovative eutectic solvent technology.


Our aim is to provide you with the information you need to make smart and strategic decisions for your drug development journey.

Benefits of HyDES platform


Up to 25% drug loading


Significant bioavailability enhancement



Physically stable


One-step manufacturing 


What drug molecule is the eutectic platform suitable for?

Perfect formulation approach for API's that are:


(Weakly) basic                                                                                High melting point

Other technologies